Durgical
EN
Open the app

Tapentadol

  • Opioids and antagonistsOpioids and antagonists
  • High alertAn error with this medicine can cause serious harm: double checks and protocols are used.

A strong opioid that also blocks noradrenaline reuptake. Used for severe acute pain; it carries all opioid risks plus serotonin syndrome.

Updated

Quick facts

Group
Opioids and antagonists
Target
μ-opioid receptor and noradrenaline transporter
Key effects
Nausea and vomiting · Dizziness · Somnolence
Monitor
Respiratory rate · Pain score
ATC
N02AX06

No doses: the clinician sets them by the current guideline.

Mechanism of action

The figure shows morphine in the μ receptor; tapentadol acts at the same site. There is no structure of tapentadol on a human target.

Target in 3D: μ-opioid receptor and noradrenaline transporter. PDB structure 8EF6 (RCSB PDB, public domain). View the structure at RCSB PDB

Tapentadol is a μ-opioid receptor agonist and a noradrenaline reuptake inhibitor in one molecule. The opioid effect reduces pain transmission and perception; the extra noradrenaline strengthens the descending pathways that inhibit pain in the spinal cord. It needs no metabolic activation.

  1. Activates μ-opioid receptors on pain pathways
  2. Also blocks noradrenaline reuptake in the spinal cord
  3. Both effects add up to analgesia

Indications

  • Acute pain severe enough to need an opioid when other treatments are not enough

Adverse effects

Common

  • Nausea and vomiting
  • Dizziness
  • Somnolence
  • Constipation

Contraindications

  • Significant respiratory depression
  • Acute or severe asthma without monitoring or resuscitation equipment
  • Known or suspected bowel obstruction, including paralytic ileus
  • MAO inhibitors now or in the last 14 days

Key interactions

Benzodiazepines, alcohol and other CNS depressants
Additive sedation and respiratory depression, with risk of death
SSRIs, SNRIs, tricyclics, triptans and other serotonergic drugs
Serotonin syndrome
MAO inhibitors
Contraindicated together or within 14 days

What is monitored

  • Respiratory rate, sedation level and oxygen saturation, above all at the start and after dose changes
  • Pain score, bowel habit and signs of misuse
  • Signs of serotonin syndrome (agitation, fever, tremor, clonus)

Administration and safety

  • Controlled medicine (Schedule II in the United States): counted, stored locked and documented
  • Oral tablets are swallowed whole; crushing or dissolving them for injection is dangerous
  • Look-alike risk with other opioids of similar name: check the name and the formulation

Pregnancy and breastfeeding

Prolonged use in pregnancy can cause neonatal opioid withdrawal syndrome.

Nursing care

  • Check breathing rate and sedation before each dose and hold the drug if the patient is hard to wake
  • Keep naloxone available and know the local overdose protocol
  • Start a bowel regimen and watch for urinary retention
  • Teach safe storage away from children, no alcohol and no driving while drowsy
  • Review antidepressants and other serotonergic drugs before the first dose

Pharmacokinetics

Absorption
About 32% bioavailable because of first-pass metabolism
Metabolism
Mainly glucuronidation; minor CYP2C9, CYP2C19 and CYP2D6 steps; no active metabolites
Elimination
Almost entirely by the kidneys
Half-life
About 4 hours

Test yourself

Think of the answer, then tap the question to see it.

Which two actions give tapentadol its analgesia?

μ-opioid agonism and noradrenaline reuptake inhibition.

Unlike tramadol, does tapentadol need a CYP2D6 metabolite to work?

No. It has no active metabolites; it is mainly glucuronidated.

Which drug class is contraindicated within 14 days?

MAO inhibitors.

Add to my cards (3)

More Pharmacology questions →

Connections

← Back to the class: Opioids and antagonists

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: DailyMed - TAPENTADOL- tapentadol hydrochloride tablet, film coated (DailyMed (U.S. National Library of Medicine), 2026); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.